The Pricing and Reimbursement Environment for Neurology DrugsDecision Resources
August 31, 2009
64 Pages - SKU: DECR2427951
More CNS/Neurology reports by Decision Resources
Niche Markets and Rare Diseases: Amyotrophic Lateral Sclerosis by Decision Resources
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease (MND), is a degenerative disorder of the nervous system ...
Migraine by Decision Resources
All the currently available triptan products, which constituted 70% of the migraine major-market sales in 2011, will face generic competition during our forecast ...
ChartTrends®: Multiple Sclerosis (EU) 2012 by Decision Resources
BioTrends Research Group is pleased to announce the continuation of ChartTrends®: Multiple Sclerosis in the EU in 2012. In this report, patient level data are ...
Generic AChEIs and Branded Disease-Modifying Therapies for Alzheimer’s Disease: How Will European Physician and Payer Attitudes Shape This Competitive Market? by Decision ResourcesSee all reports like this >>
The Alzheimer’s disease (AD) market is a source of untapped commercial potential for drug marketers because of a large and growing patient population ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Diseases & Conditions
- Alzheimer's Disease
- Insurance & Managed Care
- General Insurance & Managed Care
- Therapeutic Area